Keyword: New England Journal of Medicine
Experts question whether a pivotal trial that compared GSK's new 3-in-1 COPD drug, Trelegy, to dual-therapy drugs artificially inflated its benefits.
Full results from BMS' Opdivo monotherapy trial in first-line lung cancer are finally out—alongside a theory about why that trial came up short.
Should drugs that win conditional FDA approval command the same high prices as products that undergo the full menu of agency scrutiny?
AstraZeneca's respiratory candidate benralizumab can help some severe asthma patients cut down on the steroid pills they use to stave off attacks.
Detailed results on three ulcerative colitis trials of Pfizer's Xeljanz are out, and they could help the med snag another approval to keep sales going up.
According to research published by the New England Journal of Medicine and reported by the Wall Street Journal, shortages of prescription drug supplies in the U.S. in recent years resulted in price increases for some drugs.
Two prominent doctors have flagged a serious and unexpected side effect linked to the immuno-oncology drugs taking cancer treatment by storm: heart damage that can be fatal.
The “me-too” drug may be rehabilitated. After years of derision, the “me-too” product is getting attention from regulators as a tool for lowering drug costs--sometimes almost as much as generics.